Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Journal of Biopharmaceutical Statistics
|
September 18, 2015
Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review
Thomas Ondra, Alex Dmitrienko, Tim Friede, et al.
Critical Care Medicine
|
August 13, 2005
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis
Bernhardt G Zeiher, Jay Steingrub, Pierre-Francois Laterre, et al.
Journal of Biopharmaceutical Statistics
|
December 15, 2017
An enhanced mixture method for constructing gatekeeping procedures in clinical trials
George Kordzakhia, Thomas Brechenmacher, Eiji Ishida, et al.
Biometrical Journal. Biometrische Zeitschrift
|
April 5, 2013
Panel forum on multiple comparison procedures: a commentary from a complex trial design and analysis plan
Sue-Jane Wang, Frank Bretz, Alex Dmitrienko, et al.
Statistics in Medicine
|
June 27, 2015
Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel
Sue-Jane Wang, Frank Bretz, Alex Dmitrienko, et al.
Therapeutic Innovation & Regulatory Science
|
June 18, 2019
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, et al.
Therapeutic Innovation & Regulatory Science
|
December 10, 2020
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, et al.
JACC. Clinical Electrophysiology
|
January 22, 2021
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
Thomas F O'Connell, Christopher J Bradley, Amr E Abbas, et al.
Critical Care Medicine
|
March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure
Edward Abraham, Chris Naum, Venkata Bandi, et al.
Journal of Biopharmaceutical Statistics
|
November 21, 2007
Innovative approaches for designing and analyzing adaptive dose-ranging trials
Björn Bornkamp, Frank Bretz, Alex Dmitrienko, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Journal of Biopharmaceutical Statistics
|
September 18, 2015
Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review
Thomas Ondra, Alex Dmitrienko, Tim Friede, et al.
Critical Care Medicine
|
August 13, 2005
LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis
Bernhardt G Zeiher, Jay Steingrub, Pierre-Francois Laterre, et al.
Journal of Biopharmaceutical Statistics
|
December 15, 2017
An enhanced mixture method for constructing gatekeeping procedures in clinical trials
George Kordzakhia, Thomas Brechenmacher, Eiji Ishida, et al.
Biometrical Journal. Biometrische Zeitschrift
|
April 5, 2013
Panel forum on multiple comparison procedures: a commentary from a complex trial design and analysis plan
Sue-Jane Wang, Frank Bretz, Alex Dmitrienko, et al.
Statistics in Medicine
|
June 27, 2015
Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel
Sue-Jane Wang, Frank Bretz, Alex Dmitrienko, et al.
Therapeutic Innovation & Regulatory Science
|
June 18, 2019
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, et al.
Therapeutic Innovation & Regulatory Science
|
December 10, 2020
A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies
Christoph Muysers, Alex Dmitrienko, Hermann Kulmann, et al.
JACC. Clinical Electrophysiology
|
January 22, 2021
Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
Thomas F O'Connell, Christopher J Bradley, Amr E Abbas, et al.
Critical Care Medicine
|
March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure
Edward Abraham, Chris Naum, Venkata Bandi, et al.
Journal of Biopharmaceutical Statistics
|
November 21, 2007
Innovative approaches for designing and analyzing adaptive dose-ranging trials
Björn Bornkamp, Frank Bretz, Alex Dmitrienko, et al.
Page
of 7